WESTBURY, N.Y., Oct. 31, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will attend the American Heart Association's 2013 Scientific Sessions from November 16 – 20, 2013 in Dallas, Texas to exhibit its EECP Therapy and BIOX™ ambulatory monitoring products.
Additionally, during the Scientific Sessions, Vasomedical has teamed up with Endothelix Inc. and Ischemic Conditioning Therapeutics, Inc., both based in Houston, Texas, to co-sponsor an educational symposium focusing on the state of the art science and technology related to Endothelial Dysfunction, Enhanced External Counterpulsation (EECP), Ischemic Conditioning (ICT), and their potential interactions. This invitation-only scientific focus group event will take place on Sunday evening, November 17, 2013 from 7:00pm to 9:00pm at the Aloft Hotel in Dallas. Attendees interested in accepting the invitation should reserve their seats on the Endothelix website.
The American Heart Association's annual Scientific Sessions is one of the leading cardiovascular meetings for basic, translational, clinical and population science in the United States. Each year, more than 18,000 cardiovascular experts, from over 105 countries and approximately 1.5 million virtual professionals attend the Sessions. The event includes five days of education through more than 5,000 presentations with 1,000 invited faculty and 4,000 abstract presentations from the world's leaders in cardiovascular disease. More than 200 companies will exhibit and showcase the latest cardiovascular technology and products.
"This AHA's Scientific Sessions is one of the biggest events in cardiology in the United States. Each year, we look forward to meeting with attendees and exchanging ideas about expanding EECP Therapy's role in cardiovascular disease treatment and extolling its significant benefits to patients, providers and the healthcare system," said Larry Liebman, Vice President of Sales and Marketing at Vasomedical. "We are pleased to be co-sponsoring the educational event and to have an opportunity to contribute to a greater understanding of the importance in preserving and improving endothelial function to treat and prevent cardiovascular disease."
Vasomedical will be located in Booth #1439.
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
About Biox Instruments
Biox Instruments Co., Ltd., a wholly owned subsidiary of Vasomedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. Biox is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. Biox products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, Biox continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
SOURCE Vasomedical, Inc.